DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France,Annals of Clinical and Translational Neurology

当前位置： X-MOL 学术 › Ann. Clin. Transl. Neur. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France
Annals of Clinical and Translational Neurology ( IF 4.4 ) Pub Date : 2021-07-07 , DOI: 10.1002/acn3.51408
Maria Pia Sormani _{1,

2} , Marco Salvetti _{3,

4} , Pierre Labauge ₅ , Irene Schiavetti ₁ , Helene Zephir ₆ , Luca Carmisciano ₁ , Caroline Bensa ₇ , Nicola De Rossi ₈ , Jean Pelletier ₉ , Cinzia Cordioli ₈ , Sandra Vukusic ₁₀ , Lucia Moiola ₁₁ , Philippe Kerschen ₁₂ , Marta Radaelli ₁₃ , Marie Théaudin ₁₄ , Paolo Immovilli ₁₅ , Olivier Casez ₁₆ , Marco Capobianco ₁₇ , Jonathan Ciron ₁₈ , Maria Trojano ₁₉ , Bruno Stankoff _{20,

21} , Alain Créange ₂₂ , Gioacchino Tedeschi ₂₃ , Pierre Clavelou ₂₄ , Giancarlo Comi ₂₅ , Eric Thouvenot _{26,

27} , Mario Alberto Battaglia _{28,

29} , Thibault Moreau ₃₀ , Francesco Patti _{31,

32} , Jérôme De Sèze ₃₃ , Celine Louapre ₃₄ , ,

Affiliation

Department of Health Sciences, University of Genova, Genova, Italy.
IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Department of Neuroscience, Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy.
Unit of Neurology, IRCCS Neuromed, Pozzilli, Italy.
Department of Neurology, CHU de Montpellier, Montpellier, France.
Department of Neurology, U 1172, CRC-SEP, University Hospital of Lille, Lille, France.
Department of Neurology, Hôpital Fondation Adolphe de Rothschild, Paris, France.
Centro Sclerosi Multipla ASST Spedali Civili di Brescia, Montichiari, Italy.
Department of Neurology, Aix Marseille Univ, APHM, Hôpital de la Timone, Pôle de Neurosciences Cliniques, Marseille, 13005, France.
Service de Neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, Hospices Civils de Lyon, Hôpital Neurologique, Bron, France.
Department of Neurology, Multiple Sclerosis Center, IRCCS Ospedale San Raffaele, Milan, Italy.
Centre Hospitalier de Luxembourg, Luxembourg City, Luxembourg.
Department of Neurology and Multiple Sclerosis Center, ASST "Papa Giovanni XXIII", Bergamo, Italy.
Division of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Multiple Sclerosis Center, Ospedale Guglielmo da Saliceto, Piacenza, Italy.
Department of Neurology, University Hospital Grenoble Alpes, Neuro Inflammatory Unit, Grenoble, France.
Department of Neurology, Regional Referral Multiple Sclerosis Centre, University Hospital San Luigi, Orbassano (Torino), Italy.
Department of Neurology, CHU de Toulouse, CRC-SEP, Toulouse, France.
Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, Italy.
Sorbonne University, Paris Brain Institute, ICM, Pitié Salpêtrière Hospital, Inserm UMR S 1127, CNRS UMR 7225, Paris, France.
Neurology Department, St Antoine Hospital, APHP, Paris, France.
Service de Neurologie and CRC SEP, APHP, Groupe Hospitalier Henri Mondor, UPEC Université, Créteil, France.
Department of Advanced Medical and Surgical Sciences, University of Campania, Napoli, Italy.
University of Clermont Auvergne, CHU de Clermont-Ferrand, Inserm, Neuro-Dol, Clermont-Ferrand, France.
Institute of Experimental Neurology, IRCCS Ospedale San Raffaele, Milano, Italy.
Department of Neurology, Nîmes University Hospital, Nîmes, France.
Institute of Functional Genomics, University of Montpellier, CNRS, INSERM, Montpellier, France.
Research Department, Italian Multiple Sclerosis Foundation, Genoa, Italy.
Department of Life Sciences, University of Siena, Siena, Italy.
Department of Neurology, University hospital of Dijon, EA4184, Dijon, France.
Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, University of Catania, Catania, Italy.
Centro Sclerosi Multipla, Policlinico Catania, University of Catania, Catania, Italy.
Department of Neurology, CIC INSERM 1434, CHU de Strasbourg, Strasbourg, France.
Sorbonne University, Paris Brain Institute, ICM, Assistance Publique Hôpitaux de Paris APHP, Hôpital de la Pitié-Salpêtrière, Inserm, CNRS, CIC Neuroscience, Paris, France.

We evaluated the effect of DMTs on Covid-19 severity in patients with MS, with a pooled-analysis of two large cohorts from Italy and France. The association of baseline characteristics and DMTs with Covid-19 severity was assessed by multivariate ordinal-logistic models and pooled by a fixed-effect meta-analysis. 1066 patients with MS from Italy and 721 from France were included. In the multivariate model, anti-CD20 therapies were significantly associated (OR = 2.05, 95%CI = 1.39–3.02, p < 0.001) with Covid-19 severity, whereas interferon indicated a decreased risk (OR = 0.42, 95%CI = 0.18–0.99, p = 0.047). This pooled-analysis confirms an increased risk of severe Covid-19 in patients on anti-CD20 therapies and supports the protective role of interferon.

中文翻译：

MS 中的 DMT 和 Covid-19 严重程度：来自意大利和法国的汇总分析

我们对来自意大利和法国的两个大型队列进行了汇总分析，评估了 DMT 对 MS 患者 Covid-19 严重程度的影响。通过多变量序数逻辑模型评估基线特征和 DMT 与 Covid-19 严重程度的关联，并通过固定效应荟萃分析进行汇总。包括来自意大利的 1066 名 MS 患者和来自法国的 721 名 MS 患者。在多变量模型中，抗 CD20 疗法与 Covid-19 严重程度显着相关（OR = 2.05, 95%CI = 1.39–3.02, p < 0.001），而干扰素表明风险降低（OR = 0.42, 95%CI = 0.18–0.99，p = 0.047）。这项汇总分析证实，接受抗 CD20 治疗的患者发生严重 Covid-19 的风险增加，并支持干扰素的保护作用。

更新日期：2021-08-09

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11